Mischi a Marca

Cooley advised Xometry on its offering of $287.5 million aggregate principal amount of 1% convertible senior notes due 2027. Partners Eric Blanchard, Mischi a Marca and Jason Savich led the Cooley team advising Xometry, which provides AI-enabled manufacturing equipment.

Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.

Cooley advised the initial purchasers on Global Blood Therapeutics’ Rule 144A offering of $345 million aggregate principal amount of 1.875% Convertible Senior Notes due 2028.  In connection with the offering, GBT entered into capped call transactions. Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering. Global Blood Therapeutics is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Partners Kristin VanderPas, Charlie Kim, Dave Peinsipp, Mischi a Marca and Jason Savich led the Cooley team.

Cooley advised Dynavax Technologies on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. Dynavax Technologies, whose securities trade on the Nasdaq Capital Market under the symbol DVAX, is a biopharmaceutical company focused on developing and commercializing novel vaccines. Partners Steve Przesmicki, Mischi a Marca and Jason Savich le the Cooley team.

Cooley advised Confluent on its offering of $1.1 billion aggregate principal amount of 0.00% convertible senior notes due 2027. Confluent has pioneered a new category of data infrastructure designed to connect all the applications, systems and data layers of a company around a real-time central nervous system. Partners Mischi a Marca, Jason Savich, Jon Avina, Milson Yu and Siana Lowrey led the Cooley team.